These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 29453084)

  • 1. Solid lipid nanoparticles as an efficient drug delivery system of olmesartan medoxomil for the treatment of hypertension.
    Pandya NT; Jani P; Vanza J; Tandel H
    Colloids Surf B Biointerfaces; 2018 May; 165():37-44. PubMed ID: 29453084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Solid lipid nanoparticles as vesicles for oral delivery of olmesartan medoxomil: formulation, optimization and in vivo evaluation.
    Nooli M; Chella N; Kulhari H; Shastri NR; Sistla R
    Drug Dev Ind Pharm; 2017 Apr; 43(4):611-617. PubMed ID: 28005442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of olmesartan medoxomil optimized nanosuspension using the Box-Behnken design to improve oral bioavailability.
    Nagaraj K; Narendar D; Kishan V
    Drug Dev Ind Pharm; 2017 Jul; 43(7):1186-1196. PubMed ID: 28271908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanostructured lipid carriers of olmesartan medoxomil with enhanced oral bioavailability.
    Kaithwas V; Dora CP; Kushwah V; Jain S
    Colloids Surf B Biointerfaces; 2017 Jun; 154():10-20. PubMed ID: 28284054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, formulation and optimization of novel soft nano-carriers for transdermal olmesartan medoxomil delivery: In vitro characterization and in vivo pharmacokinetic assessment.
    Kamran M; Ahad A; Aqil M; Imam SS; Sultana Y; Ali A
    Int J Pharm; 2016 May; 505(1-2):147-58. PubMed ID: 27005906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Formulation, optimization, and in vitro-in vivo evaluation of olmesartan medoxomil nanocrystals.
    Jain S; Patel K; Arora S; Reddy VA; Dora CP
    Drug Deliv Transl Res; 2017 Apr; 7(2):292-303. PubMed ID: 28116656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of olmesartan medoxomil lipid-based nanoparticles and nanosuspension: preparation, characterization and comparative pharmacokinetic evaluation.
    B A; D N; Veerabrahma K
    Artif Cells Nanomed Biotechnol; 2018 Feb; 46(1):126-137. PubMed ID: 28290712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In Vitro and In Vivo Evaluation of Olmesartan Medoxomil Microcrysta ls and Nanocrystals: Preparation, Characterization, and Pharmacokinet ic Comparison in Beagle Dogs.
    Chai R; Gao H; Ma Z; Guo M; Fu Q; Liu H; He Z
    Curr Drug Deliv; 2019; 16(6):500-510. PubMed ID: 31244438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fabrication of Nanosuspension Directly Loaded Fast-Dissolving Films for Enhanced Oral Bioavailability of Olmesartan Medoxomil: In Vitro Characterization and Pharmacokinetic Evaluation in Healthy Human Volunteers.
    Alsofany JM; Hamza MY; Abdelbary AA
    AAPS PharmSciTech; 2018 Jul; 19(5):2118-2132. PubMed ID: 29700766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solid Lipid Nanoparticles Approach for Lymphatic Targeting Through Intraduodenal Delivery of Quetiapine Fumarate.
    Yasir M; Gaur PK; Puri D; Shehkar P; Kumar SS
    Curr Drug Deliv; 2018; 15(6):818-828. PubMed ID: 28545354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanoemulsion strategy for olmesartan medoxomil improves oral absorption and extended antihypertensive activity in hypertensive rats.
    Gorain B; Choudhury H; Kundu A; Sarkar L; Karmakar S; Jaisankar P; Pal TK
    Colloids Surf B Biointerfaces; 2014 Mar; 115():286-94. PubMed ID: 24388859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Formulation of lyophilized oily-core poly-Ɛ-caprolactone nanocapsules to improve oral bioavailability of Olmesartan Medoxomil.
    Khattab WM; Zein El-Dein EE; El-Gizawy SA
    Drug Dev Ind Pharm; 2020 May; 46(5):795-805. PubMed ID: 32275456
    [No Abstract]   [Full Text] [Related]  

  • 13. Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation.
    Dudhipala N; Veerabrahma K
    Drug Deliv; 2016; 23(2):395-404. PubMed ID: 24865287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative biodistribution and safety profiling of olmesartan medoxomil oil-in-water oral nanoemulsion.
    Gorain B; Choudhury H; Tekade RK; Karan S; Jaisankar P; Pal TK
    Regul Toxicol Pharmacol; 2016 Dec; 82():20-31. PubMed ID: 27815174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tailoring of PEGylated bilosomes for promoting the transdermal delivery of olmesartan medoxomil: in-vitro characterization, ex-vivo permeation and in-vivo assessment.
    Albash R; El-Nabarawi MA; Refai H; Abdelbary AA
    Int J Nanomedicine; 2019; 14():6555-6574. PubMed ID: 31616143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved anti-hyperlipidemic activity of Rosuvastatin Calcium via lipid nanoparticles: Pharmacokinetic and pharmacodynamic evaluation.
    Dudhipala N; Veerabrahma K
    Eur J Pharm Biopharm; 2017 Jan; 110():47-57. PubMed ID: 27810472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanocolloidal lipidic carriers of olmesartan medoxomil surface-tailored with Concavalin-A for lectin receptor targeting.
    Beg S; Choudhry H; Zamzami MA; Alharbi KS; Rahman M; Singh B
    Nanomedicine (Lond); 2018 Dec; 13(24):3107-3128. PubMed ID: 30474494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of Box-Behnken design for preparation of levofloxacin-loaded stearic acid solid lipid nanoparticles for ocular delivery: Optimization, in vitro release, ocular tolerance, and antibacterial activity.
    Baig MS; Ahad A; Aslam M; Imam SS; Aqil M; Ali A
    Int J Biol Macromol; 2016 Apr; 85():258-70. PubMed ID: 26740466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development and in vivo evaluation of an innovative "Hydrochlorothiazide-in Cyclodextrins-in Solid Lipid Nanoparticles" formulation with sustained release and enhanced oral bioavailability for potential hypertension treatment in pediatrics.
    Cirri M; Mennini N; Maestrelli F; Mura P; Ghelardini C; Di Cesare Mannelli L
    Int J Pharm; 2017 Apr; 521(1-2):73-83. PubMed ID: 28229944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. QbD-driven development and evaluation of nanostructured lipid carriers (NLCs) of Olmesartan medoxomil employing multivariate statistical techniques.
    Beg S; Saini S; Bandopadhyay S; Katare OP; Singh B
    Drug Dev Ind Pharm; 2018 Mar; 44(3):407-420. PubMed ID: 29048242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.